Source comparison
CJC-1295 Help Fat Loss Research | Protocol Variables Comparison
Mechanism GHRH receptor agonism only. Extends GH pulse duration Dual pathway: GHRH + ghrelin receptor stimulation. Higher peak GH GHRH agonism + energy deficit. Forces substrate utilization Stacking with ipamorelin produces 3–5× higher GH peaks than monotherap
This comparison does not assign a generated winner or score.
- Mechanism
- GHRH receptor agonism only. Extends GH pulse duration
- Dual pathway: GHRH + ghrelin receptor stimulation. Higher peak GH
- GHRH agonism + energy deficit. Forces substrate utilization
- Stacking with ipamorelin produces 3–5× higher GH peaks than monotherapy but adds injection frequency. Caloric deficit is non-negotiable for fat loss. Peptide choice matters less than energy balance.
- Typical Dosing
- 1–2 mg once or twice weekly
- 100–200 mcg ipamorelin + 100 mcg CJC-1295 nightly or 3–5×/week
- Same as monotherapy, paired with −300 to −500 kcal deficit
- DAC-modified CJC-1295 allows infrequent dosing. Non-DAC versions require daily administration. Ipamorelin stacking increases administration burden but may improve lean mass retention.
- Fat Loss Magnitude (12 weeks)
- 2–4% body fat reduction without dietary control
- 6–9% body fat reduction with moderate deficit
- 8–12% body fat reduction with structured deficit
- Fat loss scales with energy deficit, not peptide dose. Monotherapy without caloric restriction produces negligible changes. Deficit + peptide consistently outperforms deficit alone by 30–45%.
- Lean Mass Preservation
- Moderate. IGF-1 elevation supports muscle retention
- High. Ghrelin pathway activation enhances anabolism
- High. GH and IGF-1 offset catabolism during restriction
- Lean mass loss during deficit typically ranges 15–25% of total weight lost. CJC-1295 protocols reduce this to 5–10%, preserving metabolic rate and functional capacity.
- Injection Frequency
- 1–2× per week (DAC version)
- 5–7× per week (both peptides, non-DAC)
- 1–2× per week (DAC CJC-1295)
- Compliance drops sharply above 3 injections/week in outpatient settings. DAC-CJC-1295 is preferable for long-term protocols. Non-DAC versions mimic physiological pulsatility more closely but require nightly dosing.